Xtx Topco LTD Verve Therapeutics, Inc. Transaction History

Xtx Topco LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$10.81 - $17.96 $67,789 - $112,627	6,271 Added 58.39%	17,011 $225,000
Q4 2023 Feb 13, 2024	SELL	$8.84 - $18.7 $21,472 - $45,422	-2,429 Reduced 18.44%	10,740 $149,000
Q3 2023 Nov 13, 2023	BUY	$11.42 - $20.82 $21,378 - $38,975	1,872 Added 16.57%	13,169 $174,000
Q2 2023 Aug 14, 2023	BUY	$13.34 - $19.9 $150,701 - $224,810	11,297 New	11,297 $211,000

173

74.7M

115K

144K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $290M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.